1. Group revenue target of ₹1,000 crore - Management targets a long-term revenue goal of ₹1,000 crore, set within three to four years from FY24, with annual growth guided at 15-18% and FY27 specifically at 15-18% guaranteed. At the guided run-rate, the existing ₹671 crore base compounds toward that target while the company remains debt-free and funds all capex internally.
2. Cephalosporin facility ramp-up - The Mehsana Cephalosporin plant has commenced commercial production, crossed breakeven in Q3 FY26 with a ₹45 crore run-rate, and is projected to generate ₹150 crore in sales over three years. At 100% utilisation the plant can reach ₹220-230 crore, adding a second earnings stream that is already contributing profit.
3. Canada regulated-market exports - Exports to Canada have begun with 15-17 products commercialised via a CDMO partner, generating $3-4 million in revenue, and 23-25 products signed for development. Management expects this business to cross $10-15 million, and the January 2026 Health Canada approval of six dosage-form lines opens entry into SRA-accepting markets across Latin America and Southeast Asia.
4. EU market entry imminent - The Qualified Person audit for EU entry has been cleared and the final audit was targeted for mid-May to June, with three products already submitted for approval. The Khatraj facility has been maintained to EU standards since 2020 with costs already absorbed in current profitability, so incremental revenue from EU approvals would flow through at high marginal contribution.
5. Export country expansion from 60 to 90+ - The company aims to expand its export presence from 60+ countries to over 90 in the next 2-3 years, supported by a direct branded-marketing model with 30-35 people on the ground. Exports already contribute 60-65% of revenue, and adding 30 new geographies on the same fixed-cost base of registrations and field force can lift volumes without proportionate cost increases.
6. Existing facility utilisation headroom - The current manufacturing site still has 15-20% unutilised capacity that can be fully occupied, with peak revenue potential from the existing base (excluding Cepha) reaching ₹750-800 crore. Filling this headroom requires minimal incremental capex, so the associated revenue would convert to cash flow at above-average margins.
7. New dedicated R&D centre and pipeline scale-up - A new dedicated R&D centre has been purchased and was expected to be operational within 2-2.5 months from Q3 FY26, supporting over 100 development programmes and 30 bioequivalence studies. R&D spend is targeted to rise from 1.8-2% to 3-3.25% of revenue, and the appointment of a senior R&D leader with regulated-market experience signals a systematic push into higher-value filings.
8. CDMO/CMO project pipeline for regulated markets - The company has signed a partner for regulated-market CDMO projects, with 18-19 projects in process, 5 signed, and an expected 24-25 projects to be commercialised. These projects build a recurring, asset-light revenue stream that leverages existing regulatory approvals and plant capacity.
9. Inorganic expansion toward USFDA markets - Management has identified and initiated a process for an acquisition focused on a tableting block with suitable accreditations, with funds already committed as a first step. The stated intent is to enter markets as good as USFDA that offer better margins, which would upgrade the company's product and margin profile in a single step.